THE CONAFAY GROUP, LLC

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$10.5M

Filings

715

Unique Clients

Active Period

2012–2026

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2026	$1,150,000	44	14
2025	$1,000,000	50	13
2024	$400,000	61	18
2023	$750,000	80	21
2022	$690,000	70	20
2021	$580,000	66	18
2020	$820,000	85	22
2019	$560,000	32	9
2018	$710,000	37	10
2017	$820,000	39	13
2016	$860,000	36	9
2015	$713,812	37	8
2014	$476,000	31	10
2013	$930,000	41	11
2012	$40,000	6	3

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP	$2,890,000	58	2013–2026
MIND MEDICINE INC.	$540,000	9	2024–2026
ATEA PHARMACEUTICALS, INC.	$480,000	19	2020–2024
CEMPRA PHARMACEUTICALS	$420,000	15	2015–2017
HAWAII BIOTECH, INC.	$390,000	22	2017–2021
MESOTHELIOMA APPLIED RESEARCH FOUNDATION	$371,250	30	2014–2022
ACADIA PHARMACEUTICALS INC	$370,000	31	2018–2025
Alnylam Pharmaceuticals, Inc.	$357,562	11	2015–2017
REVAGENIX, INC.	$320,000	8	2025–2026
REALTA LIFE SCIENCES, INC.	$240,000	11	2024–2026
LIFESCIENCE LOGISTICS	$230,000	8	2024–2025
HAEMONETICS CORPORATION	$180,000	7	2012–2014
BRIGHT PATH LABORATORIES, INC.	$160,000	4	2026
ELUSYS THERAPEUTICS INC	$160,000	9	2024–2026
MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)	$160,000	23	2021–2026
WCG WIRB COPERNICUS GROUP	$150,000	6	2016–2017
ROIVANT SCIENCES, INC.	$140,000	9	2020–2022
DURATA THERAPEUTICS, INC.	$140,000	9	2014
VAXXAS INC	$130,000	17	2022–2026
SECURING AMERICAS MEDICINES AND SUPPLY SAMS	$130,000	18	2020–2025
CHIESI USA INC	$130,000	5	2018
AGILITI HEALTH INC.	$120,000	4	2026
REMPEX PHARMACEUTICALS, INC.	$120,000	8	2012–2014
BAYER HEALTHCARE	$120,000	4	2013–2014
CONAFAY GROUP LLC ON BEHALF OF MEDICAGO	$120,000	8	2013–2014

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	452
SENATE	441
Health & Human Services, Dept of (HHS)	143
Food & Drug Administration (FDA)	50
Defense, Dept of (DOD)	44
Executive Office of the President (EOP)	43
Centers For Medicare and Medicaid Services (CMS)	30
Veterans Affairs, Dept of (VA)	6
Office of Science & Technology Policy (OSTP)	4
Centers For Disease Control & Prevention (CDC)	3
Commerce, Dept of (DOC)	3
Homeland Security, Dept of (DHS)	3
Office of Management & Budget (OMB)	3

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	381
Health Issues	Health Issues	232
Budget/Appropriations	Budget/Appropriations	177
Medicare/Medicaid	Medicare/Medicaid	66
Manufacturing	Manufacturing	30
Defense	Defense	16
Science/Technology	Science/Technology	11
Disaster Planning/Emergencies	Disaster Planning/Emergencies	8
Pharmacy	Pharmacy	4

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 3437118th Congress

Colorado Outdoor Recreation and Economy Act

2023 · second_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act.

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437118th Congress

Colorado Outdoor Recreation and Economy Act

2023 · second_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act.

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437118th Congress

Colorado Outdoor Recreation and Economy Act

2023 · first_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act.

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437118th Congress

Colorado Outdoor Recreation and Economy Act

2023 · first_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act.

Client expense: — · Firm income: —

Matched citations: HR3437

Show 21 more cited filings

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · fourth_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act.

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · fourth_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act.

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · third_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · third_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · second_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · second_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · first_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2022 · first_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2021 · fourth_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2021 · fourth_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2021 · third_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

Seek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 3437117th Congress

LOANS for Biomedical Research Act

2021 · third_quarter · Client: MICROBIOME THERAPEUTICS INNOVATION GROUP (MTIG)

Open original LDA filing ↗

Cited source text and reported amounts

eek approval for regulatory support; HR3437; Loans Act

Client expense: — · Firm income: —

Matched citations: HR3437

H.R. 5293114th Congress

Department of Defense Appropriations Act, 2017

2016 · fourth_quarter · Client: ZYNERBA PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 5293

S. 3000114th Congress

Department of Defense Appropriations Act, 2017

2016 · fourth_quarter · Client: ZYNERBA PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.

Client expense: — · Firm income: $20,000

Matched citations: S. 3000

H.R. 6114th Congress

21st Century Cures Act

2016 · fourth_quarter · Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD

Client expense: — · Firm income: $60,000

Matched citations: H.R. 6

H.R. 6114th Congress

21st Century Cures Act

2016 · fourth_quarter · Client: CEMPRA PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6 - 21st Century Cures Act FDA Reform

Client expense: — · Firm income: $40,000

Matched citations: H.R. 6

H.R. 5293114th Congress

Department of Defense Appropriations Act, 2017

2016 · third_quarter · Client: ZYNERBA PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.

Client expense: — · Firm income: $20,000

Matched citations: H.R. 5293

S. 3000114th Congress

Department of Defense Appropriations Act, 2017

2016 · third_quarter · Client: ZYNERBA PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 5293 / S. 3000 - Department of Defense Appropriations Bill, 2017; seek support for PTSD treatment.

Client expense: — · Firm income: $20,000

Matched citations: S. 3000

H.R. 6114th Congress

21st Century Cures Act

2016 · third_quarter · Client: CEMPRA PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6 - 21st Century Cures Act FDA Reform

Client expense: — · Firm income: $20,000

Matched citations: H.R. 6

H.R. 6114th Congress

21st Century Cures Act

2016 · third_quarter · Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD

Client expense: — · Firm income: $60,000

Matched citations: H.R. 6

H.R. 6114th Congress

21st Century Cures Act

2016 · second_quarter · Client: CEMPRA PHARMACEUTICALS

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 6 - 21st Century Cures Act FDA Reform

Client expense: — · Firm income: $20,000

Matched citations: H.R. 6

Source: Senate LDA

THE CONAFAY GROUP, LLC — Lobbying Disclosure | Poliscope